| 1.05 -0.01 (-0.94%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.46 | 1-year : | 1.64 |
| Resists | First : | 1.25 | Second : | 1.4 |
| Pivot price | 1.12  |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.05 | MA(20) : | 1.16 |
| MA(100) : | 1.75 |
MA(250) : | 2.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.3 |
D(3) : | 19.6 |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 5.63 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALLK ] has closed above bottom band by 23.2%. Bollinger Bands are 68.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 54 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.11 |
| Low: | 1.03 - 1.04 | 1.04 - 1.05 |
| Close: | 1.04 - 1.05 | 1.05 - 1.06 |
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
Thu, 11 Apr 2024
Allakos (NASDAQ:ALLK) Trading Down 3.3% - MarketBeat
Thu, 04 Apr 2024
Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions - Yahoo Finance
Tue, 27 Feb 2024
After losing 75% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gain - Simply Wall St
Mon, 26 Feb 2024
Allakos reports potential skin inflammation treatment progress By Investing.com - Investing.com
Mon, 12 Feb 2024
How Will the Market React to Allakos Inc (ALLK) Stock Getting a Bullish Rating - InvestorsObserver
Sat, 03 Feb 2024
Allakos Inc Announces CMO Retirement and Successor - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 87.4 (%) |
| Shares Short | 5,560 (K) |
| Shares Short P.Month | 5,500 (K) |
| EPS | -2.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.91 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39 % |
| Return on Equity (ttm) | -77.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -116 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.5 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|